ORCHPHARMAOrchid Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ORCHPHARMA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 37/100)
- • Profit growth: -81.6% YoY
- • ROE: 0.6%
- • RSI: 25
- • MACD: bearish
Bull case
- • Revenue growth: 75.9% YoY
- • Debt/Equity: 0.28
- • Promoter holding: 74.5%
- • Price vs SMA200: above
Bear case
- • Profit growth: -81.6% YoY
- • ROE: 0.6%
- • RSI: 25
- • MACD: bearish
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Profit growth: -81.6% YoY
- • ROE: 0.6%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹45.03). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.